Compare CSBR & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | SER |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 56.4M |
| IPO Year | 2015 | 2024 |
| Metric | CSBR | SER |
|---|---|---|
| Price | $4.90 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 12.8K | ★ 33.3K |
| Earning Date | 09-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,900,000.00 | $130,000.00 |
| Revenue This Year | $9.83 | N/A |
| Revenue Next Year | $8.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.14 |
| 52 Week Low | $4.59 | $1.22 |
| 52 Week High | $8.31 | $5.29 |
| Indicator | CSBR | SER |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 32.43 |
| Support Level | $4.81 | $1.73 |
| Resistance Level | $6.29 | $1.86 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 45.65 | 10.60 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.